Replies to post #811 on Vascular Biogenics Ltd (VBLT)

[davidal66]

Thanks, very good synopsis. I always hated statistics.

But from a qualitative standpoint, I think the mechanics of the interim resemble the CLDX Rint. Vaccine trial. They had an interim analysis fairly late in the trial, were hoping for early stoppage, but cautioning the investment community the trial will probably not be stopped early as the bar would be too hard to beat, then were stunned that the interim suggested the vaccine was essentially futile for newly diagnosed GBM patients with 18-20 months survival in the vaccine group and 18-20 months in the sham group. Hopefully our trial will surpass these results!